A CT-Based Tumoral and Mini-Peritumoral Radiomics Approach: Differentiate Fat-Poor Angiomyolipoma from Clear Cell Renal Cell Carcinoma

基于CT的肿瘤及肿瘤周围微区放射组学方法:鉴别低脂肪血管平滑肌脂肪瘤与透明细胞肾细胞癌

阅读:1

Abstract

OBJECTIVE: This study aimed to evaluate the role of tumor and mini-peritumor in the context of CT-based radiomics analysis to differentiate fat-poor angiomyolipoma (fp-AML) from clear cell renal cell carcinoma (ccRCC). METHODS: A total of 58 fp-AMLs and 172 ccRCCs were enrolled. The volume of interest (VOI) was manually delineated in the standardized CT images and radiomics features were automatically calculated with software. After methods of feature selection, the CT-based logistic models including tumoral model (Ra-tumor), mini-peritumoral model (Ra-peritumor), perirenal model (Ra-Pr), perifat model (Ra-Pf), and tumoral+perirenal model (Ra-tumor+Pr) were constructed. The area under curves (AUCs) were calculated by DeLong test to evaluate the efficiency of logistic models. RESULTS: The AUCs of Ra-peritumor of nephrographic phase (NP) were slightly higher than those of corticomedullary phase (CMP). Furthermore, the Ra-Pr showed significant higher efficiency than the Ra-Pf, and relative more optimal radiomics features were selected in the Ra-Pr than Ra-Pf. The Ra-tumor+Pr combined tumoral and perirenal radiomics analysis was of most significant in distinction compared with Ra-tumor and Ra-peritumor. CONCLUSION: The validity of NP to differentiate fp-AML from ccRCC was slightly higher than that of CMP. To the NP analysis, the Ra-Pr was superior to the Ra-Pf in distinction, and the lesions invaded to the perirenal tissue more severely than to the perifat tissue. It is important to the individual therapeutic surgeries according to the different lesion location. The pooled tumoral and perirenal radiomics analysis was the most promising approach in distinguishing fp-AML and ccRCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。